| Literature DB >> 34902960 |
Ju Sun Heo1, Young Min Ahn2, Ai-Rhan Ellen Kim3, Son Moon Shin4.
Abstract
The recent re-emergence of vitamin D deficiency (VDD) and rickets among breastfed infants without adequate sunlight exposure and vitamin D supplementation has been reported worldwide. Breastfed infants are particularly vulnerable to VDD because of the low vitamin D content of breast milk, restricted sunlight exposure, increased pollution, and limited natural dietary sources of vitamin D. The prevalence of VDD in breastfed infants differs vastly between studies and nations at 0.6%-91.1%. The recommended intake of vitamin D for lactating mothers to optimize their overall vitamin D status and, consequently, of their breast milk is 200-2,000 IU/day, indicating a lack of consensus. Some studies have suggested that maternal high-dose vitamin D supplementation (up to 6,400 IU/day) can be used as an alternate strategy to direct infant supplementation. However, concern persists about the safety of maternal high-dose vitamin D supplementation. Direct infant supplementation is the currently available option to support vitamin D status in breastfed infants. The recommended dose for vitamin D supplementation in breastfed infants according to various societies and organizations worldwide is 200-1,200 IU/day. Most international guidelines recommend that exclusively or partially breastfed infants be supplemented with 400 IU/day of vitamin D during their first year of life. However, domestic studies on the status and guidelines for vitamin D in breastfed infants are insufficient. This review summarizes the prevalence of VDD in breastfed infants, vitamin D content of breast milk, and current guidelines for vitamin D supplementation of lactating mothers and infants to prevent VDD in breastfed infants.Entities:
Keywords: Breastfeeding; Infant; Vitamin D
Year: 2021 PMID: 34902960 PMCID: PMC9441616 DOI: 10.3345/cep.2021.00444
Source DB: PubMed Journal: Clin Exp Pediatr ISSN: 2713-4148
Definitions of deficiency, insufficiency, and sufficiency of vitamin D according to clinical guidelines
| Society/organization | Year | 25-hydroxyviamin D (ng/mL[ | ||
|---|---|---|---|---|
| Deficiency | Insufficiency | Sufficiency | ||
| Institute of Medicine [ | 2011 | <12 | 12-19 | ≥20 |
| The Endocrine Society [ | 2011 | <20 | 21–29 | ≥30 |
| European Society for Pediatric Gastroenterology Hepatology and Nutrition [ | 2013 | <20 | - | ≥20 |
| Central Europe [ | 2013 | <20 | 20–29 | ≥30 |
| Society for Adolescent Health and Medicine [ | 2013 | <20 | 20–29 | ≥30 |
| American Academy of Pediatrics [ | 2014 | <20 | - | ≥20 |
| European Food Safety Authority [ | 2016 | - | - | ≥20 |
| Global Consensus for Rickets [ | 2016 | <12 | 12–19 | ≥20 |
| Japanese Society for Bone and Mineral Research, Japan Endocrine Society [ | 2017 | <20 | 20–29 | ≥30 |
| United Arab Emirates [ | 2018 | <20 | 20–29 | ≥30 |
| Korean Society of Pediatric Endocrinology [ | 2019 | - | - | ≥20 |
| Australasia Paediatric Endocrine Group Bone and Mineral Working Group [ | 2020 | <12 | 12–19 | ≥20 |
1 ng/mL=2.5 nmol/L.
Vitamin D statuses of exclusively breastfed infants and their mothers
| First author, year | Country | No. of participants | Age of infants | 25(OH)D (ng/mL) of mothers[ | 25(OH)D (ng/mL) of infants[ | Prevalence of VDD in infants | Remark |
|---|---|---|---|---|---|---|---|
| Parian-de los Angeles et al., 2021 [ | Philippines | 131 Infants | <6 Mo | - | - | VDD (<15 ng/mL): 77% | |
| VDI (15-20 ng/mL): 10% | |||||||
| Said et al., 2020 [ | Kenya | 98 Infants | - | - | - | VDD (<12 ng/mL): 11.2% | |
| VDI (12–20 ng/mL): 12.2% | |||||||
| Trivedi et al., 2020 [ | India | 56 M-I pairs | 6 Mo | 6.29±4.11 | 6.43±3.76 | VDD (<11 ng/mL): 91.1% | Control group |
| VDI (11–19 ng/mL): 8.9% | |||||||
| Terashita et al., 2017 [ | Japan | 9 Infants | 5 Mo | - | 16.0±6.5 | VDD (<20 ng/mL): 67% | Vitamin D supplementation (-) |
| Haugen et al., 2016 [ | Nepal | 500 M-I pairs | 1–12 Mo | 21.2±8.1 | 34.8±7.6 | VDD (<12 ng/mL): 0.6% | BM (full or partly) |
| VDI (12–19 ng/mL): 3.0% | |||||||
| Salameh et al., 2016 [ | Arab in Doha, Qatar | 60 M-I pairs | 1 Mo | 13 (10–18) | 8 (5–13.5) | VDD (<20 ng/mL): 83% | |
| Wheeler et al., 2016 [ | New Zealand | 30 M-I pairs | 5 Mo | - | - | VDD (<20 ng/mL): 27% | 71% exc BM at 5 mo, control group |
| Dawodu et al., 2014 [ | USA | 120 M-I pairs | 4 Wk | 28.1±9.3 | 16.4±6.5 | VDD (<20 ng/mL): 77% | 87.5% exc BM at 4 weeks |
| Wall et al., 2013 [ | New Zealand | 94 Infants | 2–3 Mo | - | 21.2 (5.6–40) | VDD (<11 ng/mL): 24% | |
| Jain et al., 2011 [ | India | 98 M-I pairs | 2.5–3.5 Mo | 9.8 (5.0–13.8) | 10.1 (2.5–17.1) | VDD (<15 ng/mL): 66.7% | 70.6% exc BM |
| VDI (15–20 ng/mL): 19.8% | |||||||
| Agarwal et al., 2010 [ | India | 97 M-I pairs | 10 Wk | 9.34±6.18 | 11.55±7.27 | VDD (<11 ng/mL): 55.67% | |
| Kang et al., 2015 [ | South Korea | 70 M-I pairs | 4–24 Mo | 12.4±4.4 | 11.4±8.6 | VDD (≤20 ng/mL): 81% | |
| Choi et al., 2013 [ | South Korea | 52 Infants | 1–6 Mo | - | 9.35 | VDD (<20 ng/mL): 90.4% | Feeding BM>80% of total feeding volume/day |
| Kim et al., 2010 [ | South Korea | 28 M-I pairs | 0–12 Mo | 24.5±12.5 | 0 → 6 → 12 mo: 18.0±10.3 → 22.5±9.24 → 33.2±7.89 | 0 → 6 → 12 mo: VDD (<11 ng/mL) | Exc BM without supplementation |
| 26.9% → 10.7% → 0% | |||||||
| VDI (11–30 ng/mL) | |||||||
| 61.5% → 67.9% → 50.0% | |||||||
| Park et al., 1998 [ | South Korea | 18 Infants | 2–5 Mo | - | 16.0±11.3 | VDD (<11 ng/mL) 44% |
25(OH)D, 25-hydroxyvitamin D; VDD, vitamin D deficiency; VDI, vitamin D insufficiency; BM, breast milk; exc BM, exclusive breast milk; M-I, mother-infant.
Values are presented as mean±standard deviations or median (interquartile range).
Antirachitic activity of breast milk in examined studies
| Study | Year | Country | ARA of vitamin D and 25(OH)D in breast milk[ |
|---|---|---|---|
| Hollis et al., [ | 1981 | USA | Vitamin D: 1.56±0.36 IU/L |
| 25(OH)D: 62.2±6.2 IU/L | |||
| Reeve et al., [ | 1982 | USA | Vitamin D2 and D3: 14–16 IU/L |
| 25(OH)D: 33 IU/L | |||
| Ala-Houhala et al., [ | 1988 | Finland | 124 (19–332) IU/L in summer, 14 (8–30) IU/L in winter |
| Sakurai et al., [ | 2005 | Japan | Vitamin D3: 3.2±4.3 IU/L |
| Kamao et al., [ | 2007 | Japan | Vitamin D3: 3.5 IU/L |
| 25(OH)D3: 16.2 IU/L | |||
| Jan Mohamed et al., [ | 2014 | Malaysia | 25(OH)D: 80.8–100.8 IU/L |
| við Streym et al., [ | 2016 | Denmark | Vitamin D |
| Foremilk in winter: 1.6 (1.6–6.4) IU/L | |||
| Foremilk in summer: 6.4 (1.6–20.8) IU/L | |||
| Hindmilk in winter: 4.8 (1.6–14.4) IU/L | |||
| Hindmilk in summer: 14.4 (4.8–48) IU/L | |||
| 25(OH)D | |||
| Foremilk in winter: 64 (40–88) IU/L | |||
| Foremilk in summer: 72 (56–120) IU/L | |||
| Hindmilk in winter: 96 (64–128) IU/L | |||
| Hindmilk in summer: 128 (88–176) IU/L | |||
| Stoutjesdijk et al., [ | 2017 | Netherland | 46 (3–51) IU/L |
| Curaçao | 31 (5–113) IU/L | ||
| Vietnam | Halong Bay 58 (23–110) IU/L | ||
| Phu Tho 28 (1–62) IU/L | |||
| Tien Giang 63 (26–247) IU/L | |||
| Ho–Chi–Minh–City 49 (24–116) IU/L | |||
| Hanoi 37 (11–118) IU/L | |||
| Malaysia | Kuala Lumpur 14 (1–46) IU/L | ||
| Tanzania | Ukerewe 77 (12–232) IU/L | ||
| Maasai 88 (43–189) IU/L | |||
| Oberson et al., [ | 2020 | USA | 33.4–172.3 IU/L |
| Tsugawa et al., [ | 2021 | Japan | 31.3±30.3 IU/L in 1989, 25.5±12.0 IU/L in 2016–2017 |
Values are presented as mean±standard deviations or median (range).
25(OH)D, 25-hydroxyvitamin D.
ARA (calculated antirachitic activity)=biological activity of 25(OH)D+biological activity of vitamin D. Biological activity of vitamin D, 1 IU/L=25 pg/mL; biological activity of 25(OH)D, 1 IU/L=5 pg/mL.
Dietary recommended intakes (IU) of vitamin D for infants and children
| Society/organization | Age 0–1 yr | Age 1–3 yr | Age 4–10 yr |
|---|---|---|---|
| Worldwide (WHO/FAO, 2014) [ | 200 | 200 | 200 |
| Global consensus, 2016 [ | 400 | 600 | 600 |
| USA (Endocrine Society, 2011) [ | 400–1,000 | 600–1,000 | 600–1,000 |
| USA (IOM, 2011) [ | 400 | 600 | 600 |
| USA (AAP, 2014) [ | 400 | 600 | 600 |
| France (French Society of Pediatrics, 2012) [ | 1,000–1,200 | <18 mo: fortified milk 600–800, not fortified milk 1,000–1,200 | <5 yr: 2 × 80,000–100,000 (1 Nov and 1 Feb) |
| ≥18 mo: 2 × 80,000–100,000 (1 Nov and 1 Feb) | ≥5 yr: (-) | ||
| Central Europe (Polish Scientific Committee on Vitamin D, 2013) [ | 400-600 | 600–1,000 | 600–1000 |
| Europe (ESPGHAN, 2013) [ | 400 | - | - |
| Japan (DRIs, 2020) [ | 200 | Male: 120–140 | Male: 140–200 |
| Female: 140–160 | Female: 160–240 | ||
| Korea (KSPE, 2019) [ | 400 | 600 | 600 |
| Korea (DRIs by MOHW and KNS, 2020) [ | 200 | 200 | 200 |
WHO/FAO, World Health Organization/Food and Agriculture Organization; IOM, Institute of Medicine; AAP, American Academy of Pediatrics; ESPGHAN, European Society for Pediatric Gastroenterology Hepatology and Nutrition; KSPE, Korean Society of Pediatric Endocrinology; DRIs, dietary reference intakes; MOHW, Ministry of Health and Welfare; KNS, Korean Nutrition Society.
Summary of recommendations and randomized controlled trials of different doses of vitamin D for preterm infants
| Study | Population | Recommendations | |
|---|---|---|---|
| AAP, 2013 [ | <1,500 g | 200–400 IU/day | |
| ≥1,500 g | 400–1,000 IU/day | ||
| ESPGHAN, 2010 [ | <1,800 g | 800–1,000 IU/day | |
| ESPGHAN, 2019 [ | 32–36 weeks | At least 400 IU/day | |
|
|
|
|
|
| Natarajan et al., 2014 [ | 28–34 Weeks | 800 IU (n=48) vs. 400 IU (n=48) | 800 IU (vs. 400 IU) |
| - VDD at 40 weeks’ PMA↓ (38.1% vs. 66.7%) | |||
| - VDD at 3 month’s CA ↓ (12.5% vs. 35%) | |||
| - Bone mineral content, bone mineral density → | |||
| - Vitamin D excess (100–150 ng/mL): 1 (2.4%) in the 800 IU group | |||
| Fort et al., 2016 [ | 23–27 Weeks | 800 IU (n=30) vs. 200 IU (n=34) vs. placebo (n=36) | 800 IU (vs. 200 IU vs. placebo) |
| - 25(OH)D at day 28 ↑ (84.5 ng/mL vs. 39 ng/mL vs. 22 ng/mL) | |||
| - VDD (0% vs. 16% vs. 41%, | |||
| - days alive, respiratory outcomes → | |||
| Mathur et al., 2016 [ | <1,500 g | 1,000 IU (n=25) vs. 400 IU (n=25) | 1,000 IU (vs. 400 IU) |
| - Serum 25(OH)D after 6 weeks of supplementation ↑ (50.9 ng/mL vs. 29.7 ng/mL) | |||
| - VDD ↓ (0% vs. 20%) | |||
| - Calcium ↑, ALP ↓, parathyroid hormone ↓ | |||
| - Skeletal hypomineralization ↓, growth ↑ | |||
| Tergestina et al., 2016 [ | 27–34 Weeks | 1,000 IU (n=60) vs. 400 IU (n=60) | 1,000 IU (vs 400 IU) |
| - VDD at 40 weeks’ PMA ↓ (2% vs 64.6%) | |||
| - 25(OH)D at 40 weeks’ PMA ↑ (47.47 ng/mL vs. 17.48 ng/mL) | |||
| - Parathyroid hormone ↓, calcium →, phosphorus →, ALP → | |||
| - Vitamin D excess (>70 ng/mL): 9.8% of 1,000 IU group, but not associated with clinical or biochemical evidence of toxicity | |||
| - Hypercalcemia →, elevated urine calcium/creatinine → | |||
| Anderson-Berry et al., 2017 [ | 24–32 Weeks | 800 IU (n=16) vs. 400 IU (n=16) | 800 IU (vs. 400 IU) |
| - 25(OH)D at 4 weeks ↑ (42.12 ng/mL vs. 33.84 ng/mL) | |||
| - DEXA bone density measurements <10p ↓ (16% vs 56%) | |||
| Bozkurt et al., 2017 [ | 24–32 Weeks | 1,000 IU (n=40) vs. 800 IU (n=41) vs. 400 IU (n=40) | 1,000 IU (vs. 800 IU vs. 400 IU) |
| - 25(OH)D at 36 weeks’ PMA ↑ (43 ng/mL vs. 40 ng/mL vs. 29.4 ng/mL) | |||
| - VDD at 36 weeks’ PMA compared to 400 IU ↓ (2.5% vs. 22.5%) | |||
| - Vitamin D insufficiency at 36 weeks’ PMA compared to 400 IU ↓ (12% vs. 23%) | |||
| - Calcium, phosphorus, ALP, parathyroid hormone → | |||
| - Urine calcium/creatinine → | |||
| Abdel-Hady et al., 2019 [ | 28–36 Weeks with LOS | 800 IU (n=25) vs. 400 IU (n=25) | 800 IU (vs 400 IU) |
| - VDD at 40 weeks’ PMA → | |||
| - 25(OH)D at 40 weeks’ PMA ↑ (67.4 ng/mL vs. 54.8 ng/mL) | |||
| - IL-6, TNF-α, growth, duration of oxygen and respiratory support, duration of antimicrobial use, length of hospital stay, mortality → | |||
| - Vitamin D toxicity (-) |
AAP, American Academy of Pediatrics; ESPGHAN, European Society for Pediatric Gastroenterology Hepatology and Nutrition; VDD, vitamin D deficiency; PMA, postmenstrual age; CA, corrected age; 25(OH)D, 25-hydroxyvitamin D; ALP, alkaline phosphatase; DEXA, dual-energy x-ray absorptiometry; IL, interleukin; LOS, late-onset sepsis; TNF, tumor necrosis factor.
↑, significantly higher in the high-dose group; ↓, significantly lower in the high-dose group; →, no significant differences between groups.
Vitamin D contents of formulas and foods
| Formula and foods | IU per serving |
|---|---|
| Human milk fortifier, 1 pack | 30–37.5 |
| Preterm formula, 100 mL | 56–128 |
| Term formula, 100 mL | 33.2–52 |
| Cod liver oil, 1 table spoon (1 table spoon=15 mL) | 1,360 |
| Salmon, cooked, 100 g | 360 |
| Mackerel, cooked 100 g | 345 |
| Sardine, oiled and canned, 100 g | 270 |
| Eel, cooked, 100 g | 200 |
| Milk, vitamin D fortified, 200 mL | 100 |
| Egg, 1 large (vitamin D is found in yolk) | 25 |
| Mushroom, 100 g | 20 |
Source of vitamin D contents of foods: National Health Information Portal, Korea Disease Control and Prevention Agency. http://health.kdca.go.kr/healthinfo.